Objective:To assess the proportion and characteristics of young HIV-uninfected women who initiate versus do not initiate PrEP at enrollment; to assess the proportion of young women who continue and remain adherent to PrEP at Weeks 13 and 26, based on tenofovir (TFV) levels in plasma and/or dried blood spots (DBS).
Arms and Assigned Interventions
Mode of Delivery
Official Code: NCT02732730
Trial Sponsors: DAIDS, HPTN, NIAID, NIMH, Wits RHI
June 1, 2016
August 1, 2018
Age range: 16 Years ↔ 25 Years